Non-profit research organisation Biohub has released what it claims is an AI-powered "world model" of protein biology that ...
After its advisory committee voted against AstraZeneca's camizestrant as a treatment for breast cancer in April, the FDA has ...
A $140 million fund has been launched by Coefficient Giving, a health-focused philanthropic organisation, to fund R&D into ...
Roche has introduced what it says is the first comprehensive panel of certified algorithms to help manage people living with ...
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Kris Kaneta, chief product officer at Norstella, which is helping life sciences companies speed up development with instant ...
Digital medicine specialist Newel Health has formed an alliance with packaging group Gerresheimer to help pharma companies ...
Around seven years after exiting the infectious disease category, Eli Lilly is back – thanks to a trio of acquisitions worth more than $3.8 billion. At a stroke, the deals to acquire Curevo, LimmaTech ...
Sobi's $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout therapy pozdeutinurad, the main asset in the deal. The oral, once-daily URAT1 ...
AstraZeneca and Daiichi Sankyo's Datroway has been approved by the FDA for some previously untreated patients with metastatic ...
Inizio, the leading global commercialization partner to the health and life sciences industry, today announced the launch of ...
A year ago, Astellas was celebrating the first-in-class approval of its claudin 18.2-targeting cancer drug Vyloy for gastric cancers. Now, a bid to expand its label into pancreatic cancer has hit the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results